Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta‐analysis of...

por Seufert, J., Bailey, T., Barkholt Christensen, S., Nauck, M. A.
Publicado 2016

Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme

por Montanya, E., Fonseca, V., Colagiuri, S., Blonde, L., Donsmark, M., Nauck, M. A.
Publicado 2016

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study

por Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., Milicevic, Z.
Publicado 2015

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled tr...

por Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A.
Publicado 2015

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) t...

por Daniels, G H, Hegedüs, L, Marso, S P, Nauck, M A, Zinman, B, Bergenstal, R M, Mann, J F E, Derving Karsbøl, J, Moses, A C, Buse, J B, Tuttle, R M
Publicado 2015

Glucagon-like peptide 1 (GLP-1)

por Müller, T.D., Finan, B., Bloom, S.R., D'Alessio, D., Drucker, D.J., Flatt, P.R., Fritsche, A., Gribble, F., Grill, H.J., Habener, J.F., Holst, J.J., Langhans, W., Meier, J.J., Nauck, M.A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D.A., Schwartz, T.W., Seeley, R.J., Stemmer, K., Tang-Christensen, M., Woods, S.C., DiMarchi, R.D., Tschöp, M.H.
Publicado 2019